The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1253
January 29, 2007
View Complete Issue         Table of Contents 2019 
Pioglitazone/Glimepiride (Duetact) for Diabetes
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Pioglitazone/Glimepiride (Duetact) for Diabetes
January 29, 2007 (Issue: 1253)
Duetact (Takeda), a new fixed-dose combination of the thiazolidinedione pioglitazone (Actos) and the sulfonylurea glimepiride (Amaryl, and others), was recently approved by the FDA for treatment of type 2 diabetes. It is approved as an adjunct to...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Pioglitazone/Glimepiride (Duetact) for Diabetes
Article code: 1253a
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.